
|Articles|June 1, 2002
Molecule engineered to target neovascularization in AMD
A genetically engineered molecule designed to kill cancers by destroying their rapidly growing blood vessels offers a new line of attack against age-related macular degeneration (AMD) and other retinal conditions, said Alan Garen, PhD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Rayner announces Sophi Phaco System in the US
2
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
3
PRIMA retinal implant restores vision in patients with advanced GA
4
Q&A: Understanding Medicare payment shifts in eye care
5














































